- Home
- JNVR vs TOVX Comparison
JNVR vs TOVX Comparison
Compare JNVR & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JNVR
- TOVX
- Stock Information
- Founded
- JNVR 2018
- TOVX 2001
- Country
- JNVR United States
- TOVX United States
- Employees
- JNVR N/A
- TOVX N/A
- Industry
- JNVR Finance: Consumer Services
- TOVX Biotechnology: Pharmaceutical Preparations
- Sector
- JNVR Finance
- TOVX Health Care
- Exchange
- JNVR Nasdaq
- TOVX Nasdaq
- Market Cap
- JNVR 93.3M
- TOVX 3.6M
- IPO Year
- JNVR 2023
- TOVX 2006
- Fundamental
- Price
- JNVR $63.99
- TOVX $0.64
- Analyst Decision
- JNVR
- TOVX Hold
- Analyst Count
- JNVR 0
- TOVX 1
- Target Price
- JNVR N/A
- TOVX N/A
- AVG Volume (30 Days)
- JNVR 1.9M
- TOVX 2.4M
- Earning Date
- JNVR 05-13-2025
- TOVX 05-20-2025
- Dividend Yield
- JNVR N/A
- TOVX N/A
- EPS Growth
- JNVR N/A
- TOVX N/A
- EPS
- JNVR N/A
- TOVX N/A
- Revenue
- JNVR $2,099,660.00
- TOVX N/A
- Revenue This Year
- JNVR N/A
- TOVX N/A
- Revenue Next Year
- JNVR N/A
- TOVX N/A
- P/E Ratio
- JNVR N/A
- TOVX N/A
- Revenue Growth
- JNVR 4.82
- TOVX N/A
- 52 Week Low
- JNVR $3.37
- TOVX $0.74
- 52 Week High
- JNVR $91.38
- TOVX $12.25
- Technical
- Relative Strength Index (RSI)
- JNVR 57.60
- TOVX 23.36
- Support Level
- JNVR $64.09
- TOVX $1.32
- Resistance Level
- JNVR $91.38
- TOVX $1.45
- Average True Range (ATR)
- JNVR 14.99
- TOVX 0.14
- MACD
- JNVR -0.59
- TOVX -0.07
- Stochastic Oscillator
- JNVR 53.59
- TOVX 2.92
About JNVR Janover Inc.
Janover Inc is a B2B fintech marketplace providing a platform for commercial property borrowers and lenders. It provides a technology platform that connects commercial mortgage borrowers looking for debt to refinance, build, or buy commercial property including apartment buildings to commercial property lenders including banks, credit unions, REITs, debt funds, and more looking to deploy capital into commercial mortgages. The firm caters to two consumer segments: lenders and borrowers. It derives the majority of its revenue from platform fees and subscription revenue.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a lead clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system.